Tofacitinib cream for early-stage cutaneous T-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial is testing a cream called tofacitinib (a type of medicine that helps calm the immune system) for people with early-stage cutaneous T-cell lymphoma (CTCL). The goal is to see if it helps shrink or control the skin lesions safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with early-stage cutaneous T-cell lymphoma (CTCL) — stage IA, IB, or IIA.
- You have tried at least one standard treatment for your CTCL, and it either didn't work or the disease came back afterward.
- You have at least 2 separate skin lesions that can be treated.
- You are in generally good health (able to care for yourself and do daily activities).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing new treatment plans based on the genetic type of your cutaneous T-cell lymphoma (CTCL). It's for people whose CTCL did not respond well to standard skin treatments.
This study tests a cream called benvitimod to see if it helps treat a type of skin lymphoma (mycosis fungoides). It may help control skin symptoms with less harsh side effects than other treatments.
This study tests a cream that targets inflammation in the skin for people with early-stage mycosis fungoides, a type of lymphoma. It may help relieve symptoms and slow the disease without stronger treatments.
This trial looks at the results of different systemic (whole-body) treatments for cutaneous T-cell lymphoma (CTCL), a rare type of lymphoma that affects the skin. It aims to understand how well these therapies work and help guide future treatment choices.
This trial tests a spray solution applied to skin lesions caused by mycosis fungoides, a type of cutaneous T cell lymphoma. It aims to see how the spray affects bacteria on the skin and whether it helps the lesions.
This trial tests a medication called Ropeginterferon (a type of immune-supporting protein given as a shot) for people with different stages of cutaneous T-cell lymphoma. It may be an option if prior skin treatments haven't worked well enough.
Hear when a new Cutaneous T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.